🔴 Telix Pharmaceuticals is trading 7.35% down in after-hours trading; cause remains unclear

Telix Pharmaceuticals is trading at $10.34, down 7.35% in after-hours trading; available reporting does not establish a cause for the decline.

• Its Q3 2026 financial update reported US$245 million in group revenue, up 19% year over year, and reaffirmed its FY2026 outlook.
• The release also described the proposed ITM merger. Major U.S. indexes finished higher, so broad-market weakness does not explain the move; no after-hours volume or activity-level data was provided.